IBI Ag Completes $10 Million Series A Round Led by Corteva
This is the second and final tranche of IBI Ag's Series A Round for its novel bioinsecticide platform
The investment was led by Corteva ("Corteva") through its Corteva Catalyst platform, with the participation of
The completion of this
IBI Ag's proprietary technology leverages single-domain antibodies (nanobodies) to create highly effective, selective, and safe biological insect control products. Adapted from the pharmaceutical field and optimized for agriculture, this groundbreaking platform introduces new modes of action that protect high-value crops from both sucking and chewing insects, while minimizing environmental impact and preserving beneficial species.
"We're proud to have the continued confidence of our investors and to welcome
"The collaboration between IBI Ag and Corteva is a clear example of how working together can deliver innovation that increases performance and provides more sustainable solutions in crop protection," said
Corteva, through its Corteva Catalyst platform, collaborates with entrepreneurs and innovators to accelerate the development of early-stage, disruptive technologies that enable farmers to sustainably produce more food and feed.
About IBI Ag
IBI Ag is a pioneer in the Agri-biotech industry, developing innovative and sustainable crop protection solutions. The company's proprietary nanobody technology provides a new mode of action for controlling a broad range of insect pests with minimal ecological footprint. Founded by
Media Contact:
Email: Arnon.heyman@ibi-ag.com
Logo - https://mma.prnewswire.com/media/2818692/IBIAG_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/ibi-ag-completes-10-million-series-a-round-led-by-corteva-302611427.html
SOURCE IBI Ag